Insulin inhalation (Novo Nordisk)

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameInsulin inhalation (Novo Nordisk)
Drug Alias NameAERx iDMSNN-1998
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionPhosphokinases stimulantsOrnithine decarboxylase stimulants
TargetsPhosphokinasesOrnithine decarboxylase
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Diabetes Mellitus +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFormer Serbia and MontenegroBelgiumBulgaria +[33] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAradigm
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovo Nordisk A/S
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Diabetes Mellitus +[4] 

Other Information

ATC CodeA10AB01A10AC01A10AD01 +[5] 
Related LinksN/A